• Home
  • Media
  • News
  • LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management

LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management

Ballerup, Denmark, May 10, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced the appointment of Beth-Anne Lang, Vice President and Head of Global Regulatory Affairs and Christine Garrett, Vice President and Head of Global Project Management. Both will join LEO Pharma on May 13.

Beth-Anne Lang and Christine Garrett will be based in Madison, New Jersey and be part of LEO Pharma's Global Development Team. Beth-Anne's main responsibility will be to lead and transform the regulatory into an even more modern and global organization and in this way support and accelerate LEO Pharma's development of innovative dermatologic therapies to patients around the world. Christine Garrett's main responsibility will be to lead a new program management organization which will be key for LEO Pharma in order to strengthen the company's global drug development capabilities and help make innovation available to patients faster.

LEO Pharma's Global Development Team plays an important role in the execution of the company's 2025 strategy. As part of the strategy, LEO Pharma R&D has launched a series of initiatives to raise the bar scientifically and build new capabilities within rare diseases, disease understanding and precision medicine within the company – supported by new ways of working with data and advanced analytics. Among other, this includes the recent addition of a new Translational Medicine Unit in Boston.

LEO Pharma is building the world's best dermatology R&D organization, nothing less. The appointment of Beth-Anne Lang and Christine Garrett is a key milestone in achieving this ambition.
Christian Antoni
Senior Vice President, Global Development
LEO Pharma

Beth-Anne Lang and Christine Garrett will be based in Madison, New Jersey and be part of LEO Pharma's Global Development Team. Beth-Anne's main responsibility will be to lead and transform the regulatory into an even more modern and global organization and in this way support and accelerate LEO Pharma's development of innovative dermatologic therapies to patients around the world. Christine Garrett's main responsibility will be to lead a new program management organization which will be key for LEO Pharma in order to strengthen the company's global drug development capabilities and help make innovation available to patients faster.

LEO Pharma's Global Development Team plays an important role in the execution of the company's 2025 strategy. As part of the strategy, LEO Pharma R&D has launched a series of initiatives to raise the bar scientifically and build new capabilities within rare diseases, disease understanding and precision medicine within the company – supported by new ways of working with data and advanced analytics. Among other, this includes the recent addition of a new Translational Medicine Unit in Boston.

LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit.

Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million.

CONTACT US

Trine Juul Wengel

Global External Communication
Tel: +45 2073 2037